LIANG Wen-xin
Department of Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China;ZHOU Wei-ying
Department of Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China;LI Fei
Department of Hematology, First Medical Center, Chinese PLA General Hospital, Beijing 100853, ChinaXU Juan
Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center, Chinese PLA General Hospital, Beijing 100853, ChinaBAI Nan
Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center, Chinese PLA General Hospital, Beijing 100853, ChinaCAI Yun
Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center, Chinese PLA General Hospital, Beijing 100853, ChinaWANG Ting-ting
Department of Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China;1.Department of Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China;2.Chongqing Key Laboratory of Drug Metabolism Research, Chongqing 400016, China;3.Department of Hematology, First Medical Center, Chinese PLA General Hospital, Beijing 100853, China;4.Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center, Chinese PLA General Hospital, Beijing 100853, China
R733;R519
梁文馨,周维英,李菲,等.两性霉素B在恶性血液病合并侵袭性真菌病患者中的临床应用[J].中国感染控制杂志,2022,(11):1068-1074. DOI:10.12138/j. issn.1671-9638.20223072.
Wen-xin LIANG, Wei-ying ZHOU, Fei LI, et al. Clinical use of amphotericin B in patients with malignant hematological diseases combined with invasive fungal disease[J]. Chin J Infect Control, 2022,(11):1068-1074. DOI:10.12138/j. issn.1671-9638.20223072.